SEARCH

SEARCH BY CITATION

References

  • 1
    Hanauer SB, Sandborn W. Management of Crohn's disease in adults. Am J Gastroenterol 2001; 96: 63543.
    Direct Link:
  • 2
    Summers RW, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979; 77: 84769.
  • 3
    Malchow H, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984; 86: 24966.
  • 4
    Singleton JW, et al. A trial of sulfasalazine as adjunctive therapy in Crohn's disease. Gastroenterology 1979; 77: 88797.
  • 5
    Rijk MC, Van Hogezand RA, Van Lier HJ, et al. Sulphasalazine and prednisone compared with sulphasalazine for treating active Crohn disease. A double-blind, randomized, multicenter trial . Ann Intern Med 1991; 114: 44550.
  • 6
    Anthonisen P, Barany F, Folkenborg O, et al. The clinical effect of salazosulphapyridine (Salazopyrin R) in Crohn's disease. Scand J Gastroenterol 1974; 9: 54954.
  • 7
    Van Hees PA, Van Lier HJ, Van Elteren PH, et al. Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study. Gut 1981; 22: 4049.
  • 8
    Das KM, Eastwood MA, McManus JP, et al. The relationship between metabolites and the response to treatment in inpatients. Gut 1973; 14: 63141.
  • 9
    Taffet SL, Das KM. Sulfasalazine. Adverse effects and desensitization. Dig Dis Sci 1983; 28: 83342.
  • 10
    Das KM, Eastwood MA, McManus JP, et al. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 1973; 289: 4915.
  • 11
    Rasmussen SN, Lauritsen K, Tage-Jensen U, et al. 5-Aminosalicylic acid in the treatment of Crohn's disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa. Scand J Gastroenterol 1987; 22: 87783.
  • 12
    Mahida YR, Jewell DP. Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn's disease. Digestion 1990; 45: 8892.
  • 13
    Singleton JW, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Dis Study Group. Gastroenterol 1993; 104: 1293301.
  • 14
    Singleton J. Second trial of mesalamine therapy in the treatment of active Crohn's disease. Gastroenterology 1994; 107: 6323.
  • 15
    Tremaine WJ, Schroeder KW, Harrison JM, et al. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. J Clin Gastroenterol 1994; 19: 27882.
  • 16
    Hanauer SB, Stromberg U. Efficacy of oral Pentasa 4 g/day in treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials. Gastroenterology 2001; 120: A453 (Abstract).
  • 17
    Thomsen OÖ, Cortot A, Jewell D, et al. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide–Mesalamine Study Group. N Engl J Med 1998; 339: 3704.
  • 18
    Scholmerich J, Jenss H, Hartmann F, et al. Oral 5-aminosalicylic acid versus 6-methylprenisolone in active Crohn's disease. Can J Gastroenterol 1990; 4: 44651.
  • 19
    Martin F, Sutherland L, Beck IT, et al. Oral 5-ASA versus prednisone in short term treatment of Crohn's disease: a multicentre controlled trial. Can J Gastroenterol 1990; 4: 4527.
  • 20
    Gross V, Andus T, Fischbach W, et al. Comparison between high dose 5-aminosalicylic acid and 6-methylprednisolone in active Crohn's ileocolitis. A multicenter randomized double-blind study. German 5-ASA Study Group. Z Gastroenterol 1995; 33: 5814.
  • 21
    Prantera C, Cottone M, Pallone F, et al. Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial. Gastroenterology 1999; 116: 5216.
  • 22
    Yang YX, Lichtenstein GR. Corticosteroids in Crohn's disease. Am J Gastroenterol 2002; 97: 80323.
    Direct Link:
  • 23
    Singleton JW, Law DH, Kelley ML, et al. National Cooperative Crohn's Disease Study: adverse reactions to study drugs. Gastroenterology 1979; 77: 87082.
  • 24
    Campieri M, Ferguson A, Doe W, et al. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut 1997; 41: 20914.
  • 25
    Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994; 331: 83641.
  • 26
    Gross V, Andus T, Caesar I, et al. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group. Eur J Gastroenterol Hepatol 1996; 8: 9059.
  • 27
    Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994; 331: 8425.
  • 28
    Tremaine WJ, Hanauer SB, Katz S, et al. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol 2002; 97: 174854.
    Direct Link:
  • 29
    Bar-Meir S, Chowers Y, Lavy A, et al. Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group. Gastroenterol 1998; 115: 83540.
  • 30
    Kane SV, Schoenfeld P, Sandborn WJ, et al. Systematic review: The effectiveness of budesonide therapy for Crohn's disease. Aliment Pharmacol Ther 2002; 16: 150917.
  • 31
    Lyckegaard E, Hakansson K, Bengtsson B. Compassionate use of budesonide capsules (ENTOCORT EC) in patients with Crohn's disease. Gastroenterology 2002; 122: T1665.
  • 32
    Sutherland L, Singleton J, Sessions J, et al. Double blind. placebo controlled trial of metronidazole in Crohn's disease. Gut 1991; 32: 10715.
  • 33
    Allan R, Cooke W. Evaluation of metronidazole in the management of Crohn's disease. Gut 1977; 18: A422 (Abstract).
  • 34
    Ambrose NS, Allan RN, Keighley MR, et al. Antibiotic therapy for treatment in relapse of intestinal Crohn's disease. A prospective randomized study. Dis Colon Rectum 1985; 28: 815.
  • 35
    Blichfeldt P, Blomhoff JP, Myhre E, et al. Metronidazole in Crohn's disease. A double blind cross-over clinical trial. Scand J Gastroenterol 1978; 13: 1237.
  • 36
    Ursing B, Alm T, Barany F, et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result. Gastroenterology 1982; 83: 55062.
  • 37
    Rosen A, Ursing B, Alm T, et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. I. Design and methodologic considerations. Gastroenterology 1982; 83: 5419.
  • 38
    Sibbald B, Roberts C. Understanding controlled trials. Crossover trials. Br Med J 1998; 316: 1719.
  • 39
    Arnold GL, Beaves MR, Pryjdun VO, et al. Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm Bowel Dis 2002; 8: 105.
  • 40
    Steinhart AH, Feagan BG, Wong CJ, et al. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology 2002; 123: 3340.
  • 41
    Colombel JF, Lemann M, Cassagnou M, et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol 1999; 94: 6748.
    Direct Link:
  • 42
    Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996; 91: 32832.
  • 43
    Stein RB, Hanauer SB. Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf 2000; 23: 42948.
  • 44
    Duffy LF, Daum F, Fisher SE, et al. Peripheral neuropathy in Crohn's disease patients treated with metronidazole. Gastroenterology 1985; 88: 6814.
  • 45
    Goldman P. Metronidazole: proven benefits and potential risks. Johns Hopkins Med J 1980; 147: 19.
  • 46
    Roe FJ. Toxicologic evaluation of metronidazole with particular reference to carcinogenic, mutagenic, and teratogenic potential. Surgery 1983; 93: 15864.
  • 47
    Krause JR, Ayuyang HQ, Ellis LD. Occurrence of three cases of carcinoma in individuals with Crohn's disease treated with metronidazole. Am J Gastroenterol 1985; 80: 97882.
  • 48
    Svartz N. Salazopyrin, a new sulfanilamide preparation: A. Therapeutic results in rheumatic polyarthritis. B. Therapeutic results in ulcerative colitis. Acta Med Scand 1942; 110: 55790.
  • 49
    Azad-Kahn A, Piris J, Truelove S. An experiment to determine the active therapeutic moiety of sulfasalazine. Lancet 1977; 2: 8925.
  • 50
    Van Hees P, . Bakker J, Van Tongeren J. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulfasalazine. Gut 1980; 21: 6325.
  • 51
    Klotz U, Maier K, Fischer C, et al. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N Engl J Med 1980; 303: 1499502.
  • 52
    Saverymuttu S, Hodgson HJ, Chadwick VS. Controlled trial comparing prednisolone with an elemental diet plus non- absorbable antibiotics in active Crohn's disease. Gut 1985; 26: 9948.
  • 53
    O'Morain CAW, Segal, Levi. Elemental Diet as Primary Treatment of Acute Crohn's Disease: a Controlled Trial. Br Med J (Clin Res Edn) 1984; 288: 185962.
  • 54
    Sanderson IR, Udeen S, Davies PS, et al. Remission induced by an elemental diet in small bowel Crohn's disease. Arch Dis Child 1987; 62: 1237.
  • 55
    Malchow H, Steinhardt HJ, Lorenz-Meyer H, et al. Feasibility and effectiveness of a defined-formula diet regimen in treating active Crohn's disease. European Cooperative Crohn's Disease Study III. Scand J Gastroenterol 1990; 25: 23544.
  • 56
    Lochs H, Steinhardt HJ, Klaus-Wentz B, et al. Comparison of enteral nutrition and drug treatment in active Crohn's disease. Results of the European Cooperative Crohn's Disease Study. IV. Gastroenterology 1991; 101: 8818.
  • 57
    Lindor KD, Fleming CR, Burnes JU, et al. A randomized prospective trial comparing a defined formula diet, corticosteroids, and a defined formula diet plus corticosteroids in active Crohn's disease. Mayo Clin Proc 1992; 67: 32833.
  • 58
    Gonzalez-Huix F, De Leon R, Fernandez-Banares F, et al. Polymeric enteral diets as primary treatment of active Crohn's disease: a prospective steroid controlled trial. Gut 1993; 34: 77882.
  • 59
    Belli DC, Seidman E, Bouthillier L, et al. Chronic intermittent elemental diet improves growth failure in children with Crohn's disease. Gastroenterology 1988; 94: 10.
  • 60
    Ruuska T, Savilahti E, Maki M, et al. Exclusive whole protein enteral diet versus prednisolone in the treatment of acute Crohn's disease in children. J Pediatr Gastroenterol Nutr 1994; 19: 17580.
  • 61
    Griffiths AM, Ohlsson A, Sherman PM, et al. Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease. Gastroenterology 1995; 108: 105667.
  • 62
    Bitton A, Peppercorn MA, Hanrahan JP, et al. Mesalamine-induced lung toxicity. Am J Gastroenterol 1996; 91: 103940.
  • 63
    Iaquinto G, Sorrentini I, Petillo FE, et al. Pleuropericarditis in a patient with ulcerative colitis in long-standing 5-aminosalicylic acid therapy. Ital J Gastroenterol 1994; 26: 1457.
  • 64
    Deltenre P, Berson A, Marcellin P, et al. Mesalazine (5-aminosalicylic acid) induced chronic hepatitis. Gut 1999; 44: 8868.
  • 65
    Fernandez J, Sala M, Panes J, et al. Acute pancreatitis after long-term 5-aminosalicylic acid therapy. Am J Gastroenterol 1997; 92: 23023.
  • 66
    Brouillard M, Gheerbrant JD, Gheysens Y, et al. Chronic interstitial nephritis and mesalazine: 3 new cases? Gastroenterol Clin Biol 1998; 22: 7246.
  • 67
    Calvino J, Romero R, Pintos E, et al. Mesalazine-associated tubulo-interstitial nephritis in inflammatory bowel disease. Clin Nephrol 1998; 49: 2657.
  • 68
    Colombel JF, Brabant G, Gubler MC, et al. Renal insufficiency in infants: side-effect of prenatal exposure to mesalazine? Lancet 1994; 344: 6201.
  • 69
    Corrigan G, Stevens P. Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther 2000; 14: 16.
  • 70
    D'Haens G, Verstraete A, Cheyns K, et al. Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease. Aliment Pharmacol Ther 1998; 12: 41924.